Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

Breadcrumb trail:

Infectious Disease Board Exam Committee

Expand All | Collapse All

Randall S. Edson, MD, Chair

Randall S. Edson, MD, ChairDr. Edson is currently the Internal Medicine Program Director at California Pacific Medical Center, San Francisco, California and also Clinical Professor of Medicine at the University of California San Francisco. He is board certified in both Internal Medicine and Infectious Disease.

Previously, Dr. Edson was Professor of Medicine at the Mayo Clinic College of Medicine and had a 32-year career as an infectious diseases clinician and internal medicine clinician/educator. While at Mayo, Dr. Edson served as Program Director for the Infectious Diseases Fellowship Program and was a Senior Associate Program Director for the Internal Medicine Residency Program. In 2013, he was a recipient of the Distinguished Mayo Clinician award.

Dr. Edson currently serves on the Governor's Advisory Board for the Northern California Chapter of the American College of Physicians (ACP) and is Program Chair for the 2015 Annual Meeting of the All California Chapter of the ACP. Dr. Edson is Chair of the American Board of Internal Medicine (ABIM) Infectious Disease Board Exam Committee. He previously served on the ABIM Internal Medicine Exam Committee. He was awarded mastership in the American College of Physicians in April 2013.

Dr. Edson received a bachelor's degree in music history at Yale College and a master's degree in music from the Yale School of Music. He attended medical school at the University of Iowa and completed internal medicine residency and infectious diseases fellowship training at the Mayo School of Graduate Medical Education.

As of January 2017, Dr. Edson reported the following external relationships:

Dr. Edson serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Physicians, Program Chair for the California Chapter Meeting, without compensation.
  • American College of Physicians, Member of ACP Governor's Advisory Board, without compensation.

John W. Baddley, MD, MSPH

John W. Baddley, MDDr. Baddley is a Professor of Medicine, Division of Infectious Diseases, at the University of Alabama at Birmingham (UAB). Dr. Baddley serves as Director, Transplant Infectious Diseases in the UAB Comprehensive Transplant Institute and as Chief of Infectious Diseases at the Birmingham VA Medical Center.

Dr. Baddley is board certified in infectious disease. He serves as a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee. Dr. Baddley's research interests include the epidemiology, diagnosis and treatment of fungal infections; transplant infectious diseases; and infections associated with biologic therapies. He has authored or co-authored more than 150 papers, chapters and reviews. He also serves as an Associate Editor for Open Forum Infectious Diseases.

Dr. Baddley received his medical degree from Louisiana State University (LSU) School of Medicine, New Orleans. He completed an internship and residency at LSU Medical Center, and a fellowship in infectious diseases at University of Alabama at Birmingham, where he served as Chief Infectious Diseases Fellow.

As of August 2018, Dr. Baddley reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to the University of Alabama, from the following companies:

  • Shire, for a study of maribavir versus stand-of-care for the treatment of refractory or resistant cytomegalovirus in transplant patients.

Service on data and safety monitoring boards for the following companies, with honoraria:

  • R-Pharm/Ruintiles, relating to olokizumab and focusing on infection-related events, receiving honoraria.

Service on a research-related expert panel or advisory board for the following companies, with honoraria:

  • Pfizer, for service on an adjudication committee than evaluates opportunistic infections among patients participating in clinical trials for tofacitinib.

Christina M. Coyle, MD

Dr. Coyle is Professor of Clinical Medicine, specializing in infectious diseases, at The Albert Einstein College of Medicine. In 2007, she became the Assistant Dean for Faculty Development. Dr. Coyle is board certified in Infectious Disease and has special expertise in parasitology. She is a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee.

Dr. Coyle is recognized as an expert in the larval tapeworms, Echinococcus, and in neurocysticercosis. She has co-authored chapters and articles on these and many other tropical diseases. She has run an active tropical medicine clinic in the United States since 2006. In 2007, she became a site director for GeoSentinel, the global surveillance network of the International Society of Travel Medicine and the Centers for Disease Control. She also functions in the Infectious Disease Society of America and American Society Tropical Medicine and Hygiene (ASTM&H) panel on guidelines for neurocysticercosis. In addition, she co-directs the annual ASTM&H Update Course since 2008, which provides clinically relevant education in the field of tropical medicine and parasitology, in order to reduce global health disparities.

Dr. Coyle is a deeply committed educator. Since her faculty appointment at Einstein in 1995, she has served in many different roles in medical education and has been the recipient of almost every teaching award at Einstein. In 2007, she was appointed Course Director of Parasitology and Global Medicine Course in the second-year medical student curriculum, the only free-standing tropical medicine course at a U.S. medical school. Dr. Coyle is a much-sought-after teacher and lectures frequently at other medical schools in New York City. As of 2010, she also lectures in the parasitology section of the microbiology course at Columbia Medical School in New York City.

Dr. Coyle is a graduate of Adelphi University and earned her medical degree at State University of New York-Downstate Medical Center. She completed her residency in internal medicine and a fellowship in infectious diseases at Bronx Municipal Hospital Center, and also holds a master of clinical research degree from Einstein.

As of January 2019, Dr. Coyle reported no external relationships.

Kimberly Hanson, MD

Kimberly Hanson, MDDr. Hanson is an Associate Professor of Medicine and Pathology. She is Director of the Transplant Infectious Diseases and Immunocompromised Host Service at the University of Utah and Section Head for Clinical Microbiology within ARUP Laboratories.

Previously, Dr. Hanson was a faculty member and Associate Director of the Molecular Microbiology Laboratory at Duke University Medical Center.

Dr. Hanson is board certified in both Infectious Disease and Medical Microbiology. She serves as a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee.

Dr. Hanson received her undergraduate and medical degrees from Northwestern University. She completed internal medicine training and was chief medical resident at Dartmouth-Hitchcock Medical Center. She then completed adult infectious diseases and medical microbiology fellowships at Duke University, followed by a master’s degree in health sciences from the same institution.

As of January 2017, Dr. Hanson reported the following external relationships:

Service on research-related panel or advisory boards for the following companies, with compensation as listed:

  • Astellas, advising on the use and marketing messages for antifungal drugs, receiving honoraria.

Dr. Hanson serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Infectious Diseases Society of America, Diagnostics Policy Task Force member, without support.
  • Clinical Laboratory Standards Institute, Subcommittee on antifungal susceptibility testing, without support.
  • Infectious Diseases Society of America, Associate Editor, receiving consulting fees.

Howard M. Heller, MD

Howard M. Heller, MDDr. Heller is board certified in Internal Medicine and Infectious Disease. He is Associate Medical Director at the Massachusetts Institute of Technology (MIT), Associate Physician at Massachusetts General Hospital (MGH) in the infectious disease unit and Assistant Clinical Professor of Medicine, part-time, at Harvard Medical School.

At MIT, Dr. Heller practices primary care medicine and infectious disease and, as Associate Medical Director, is responsible for performance improvement, primary care, pediatrics, OB/GYN and mental health. He teaches in the Harvard-MIT Health Science and Technology (HST) program. At MGH, Dr. Heller serves on the infectious disease consult service, teaching and providing clinical care. He is a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee.

Dr. Heller has previously served as President of the Massachusetts Infectious Disease Society and is currently a member of the board. He previously served on several committees of the AIDS Clinical Trial Group of the National Institutes of Health and was co-investigator of several clinical trials.

Dr. Heller received a bachelor's degree in biology from Columbia College of Columbia University and his medical degree from SUNY-Upstate Medical University, (Syracuse). He trained in internal medicine at North Shore University Hospital/ Memorial Sloan Kettering Cancer Center (Cornell) and completed a fellowship in infectious diseases at SUNY-Stony Brook. He received a master's of public health degree from the Mailman School of Public Health of Columbia University. He is a Fellow of the Infectious Disease Society of America.

As of January 2017, Dr. Heller reported the following external relationships:

Work as an author or editor for following company, with compensation as listed:

  • UpToDate, receiving compensation for authorship.

Dr. Heller serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Massachusetts Infectious Disease Society, Board Member and Treasurer, without compensation.

Paul E. Sax, MD

Paul E. Sax, MDDr. Sax is Clinical Director of the Division of Infectious Diseases and the HIV Program at Brigham and Women's Hospital (BWH), and Professor of Medicine at Harvard Medical School. He is board certified in Internal Medicine and Infectious Diseases.

Dr. Sax is Editor-in-Chief of Open Forum Infectious Diseases, is on the Peer Review Board of the HIV/AIDS Section of UpToDate, and the Editorial Advisory Board of Medscape HIV/AIDS. Dr. Sax is also on the core faculty of the International AIDS Society - USA and the New England AIDS Education and Training Center. In addition to his clinical and teaching work, Dr. Sax's ongoing areas of research include clinical trials of antiretroviral therapies, cost-effectiveness of management strategies for HIV, and toxicity of antiretroviral therapy. He is presently the Principal Investigator at the BWH AIDS Clinical Trials Unit and is a member of the Cost-Effectiveness of Preventing AIDS Complications Research Group. He serves as a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee.

Dr. Sax received his medical degree from Harvard Medical School in 1987. He served his residency in internal medicine at BWH, while continuing his postdoctoral education with a fellowship in the Infectious Disease Unit of Massachusetts General Hospital.

As of January 2017, Dr. Sax reported the following external relationships.

Funding for clinical trial expenses and staff, paid to Brigham and Women's Hospital, from the following companies:

  • Bristol-Myers Squibb, to study atazanavir for endothelial dysfunction.
  • ViiV Healthcare, for a study of lamivudine and dolutegravir for HIV infection.

Service on a data and safety monitoring board for the following company, with compensation as listed:

  • Janssen Pharmaceuticals, for a study of darunavir plus cobicista-emtricitabine plus tenofovir alafenamide for treatment of HIV infection.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • AbbVie, to advise on treatments for hepatitis C infection, receiving reimbursement for travel expenses and honoraria.
  • Bristol-Myers Squibb, to advise on treatments for HIV infection, receiving reimbursement for travel expenses and honoraria.
  • Gilead, to advise on treatments for HIV and hepatitis C infection, receiving reimbursement for travel expenses and honoraria.
  • Merck & Co., to advise on treatments for HIV, hepatitis C and other infectious diseases, receiving reimbursement for travel expenses and honoraria.
  • ViiV Healthcare, to advise on treatments for HIV infection, receiving reimbursement for travel expenses and honoraria.

Industry-supported continuing medical education supported by the following, with compensation as listed:

  • ViiV Healthcare, for HIV-related educational activities, receiving reimbursement for travel expenses and honoraria.
  • Janssen Pharmaceuticals, for HIV-related educational activities, receiving reimbursement for travel expenses and honoraria.

Work as an author or editor for following companies, with compensation as listed:

  • Infectious Diseases Society of America, receiving salary support for service as Editor-in-Chief of Open Forum Infectious Diseases.
  • UpToDate, receiving compensation as an author.

Costi Sifri, MD

Bio coming soon.

As of July 2018, Dr. Sifri reported no ongoing external relationship.

Stephen C. Threlkeld, MD

Stephen C. Threlkeld, MDDr. Threlkeld is board certified in Infectious Disease and has been Managing Partner of an infectious disease group practice for the past 20 years. He is an Assistant Clinical Professor of Medicine at the University of Tennessee Center for the Health Sciences. He also serves as epidemiologist and Infectious Disease Director of the Baptist Memorial Hospital Heart Lung Transplant Program, as well as co-Chair of the Infection Control Committee and Chairman of the System Antibiotic Stewardship Committee at Baptist Memorial Hospital. He is a member of the Mycoses Study Group Education and Research Consortium and a member of the Infectious Disease Society of America.

He has previously served as Chief of Staff, Department of Medicine Chairman, Formulary Committee Chairman, and as a member of the Metropolitan Board of Directors at Baptist Memorial Hospital in Memphis. Currently, Dr. Threlkeld serves as a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee.

He received his undergraduate degree at Rhodes College and attended the University of Alabama medical school in Birmingham (UAB). He completed internal medicine residency and a Chief Medical Resident year at UAB. He then completed a fellowship in infectious disease at Massachusetts General Hospital and received the Massachusetts Infectious Disease Society Edward H. Kass Award for Clinical Excellence.

As of July 2017, Dr. Threlkeld reported the following external relationships.

Dr. Threlkeld serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Baptist Memorial Health Care Corporation, Epidemiologist, Member of Baptist Cardiac Transplant Program, receiving compensation for transplant committee weekly meetings.